Control of Tyrosine Kinase Signalling by Small Adaptors in Colorectal Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 May 17

PMID 31091767

Citations 6

Authors

Rudy Mevizou

Audrey Sirvent

Serge Roche

Affiliations

Soon will be listed here.

Abstract

Tyrosine kinases (TKs) phosphorylate proteins on tyrosine residues as an intracellular signalling mechanism to coordinate intestinal epithelial cell communication and fate decision. Deregulation of their activity is ultimately connected with carcinogenesis. In colorectal cancer (CRC), it is still unclear how aberrant TK activities contribute to tumour formation because TK-encoding genes are not frequently mutated in this cancer. In vertebrates, several TKs are under the control of small adaptor proteins with potential important physiopathological roles. For instance, they can exert tumour suppressor functions in human cancer by targeting several components of the oncogenic TK signalling cascades. Here, we review how the Src-like adaptor protein (SLAP) and the suppressor of cytokine signalling (SOCS) adaptor proteins regulate the SRC and the Janus kinase (JAK) oncogenic pathways, respectively, and how their loss of function in the intestinal epithelium may influence tumour formation. We also discuss the potential therapeutic value of these adaptors in CRC.

Citing Articles

Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics.

Valdeolivas A, Amberg B, Giroud N, Richardson M, Galvez E, Badillo S NPJ Precis Oncol. 2024; 8(1):10.

PMID: 38200223 PMC: 10781769. DOI: 10.1038/s41698-023-00488-4.

Posttranslational control of lipogenesis in the tumor microenvironment.

Zhu Y, Lin X, Zhou X, Prochownik E, Wang F, Li Y J Hematol Oncol. 2022; 15(1):120.

PMID: 36038892 PMC: 9422141. DOI: 10.1186/s13045-022-01340-1.

Oncogenic Signalling of PEAK2 Pseudokinase in Colon Cancer.

Lecointre C, Fourgous E, Montarras I, Kerneur C, Simon V, Boublik Y Cancers (Basel). 2022; 14(12).

PMID: 35740644 PMC: 9221080. DOI: 10.3390/cancers14122981.

Identification of Gene Co-Expression Networks Associated with Consensus Molecular Subtype-1 of Colorectal Cancer.

Nunez S, Young C, Griffen T, Ohandjo A, McKinney L, Kopetz S Cancers (Basel). 2021; 13(22).

PMID: 34830978 PMC: 8616344. DOI: 10.3390/cancers13225824.

Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis.

Sirvent A, Mevizou R, Naim D, Lafitte M, Roche S Cancers (Basel). 2020; 12(8).

PMID: 32717909 PMC: 7464719. DOI: 10.3390/cancers12082014.

References

Aringer M, Cheng A, Nelson J, Chen M, Sudarshan C, Zhou Y . Janus kinases and their role in growth and disease. Life Sci. 1999; 64(24):2173-86. DOI: 10.1016/s0024-3205(98)00538-4. View

Manes G, Bello P, Roche S . Slap negatively regulates Src mitogenic function but does not revert Src-induced cell morphology changes. Mol Cell Biol. 2000; 20(10):3396-406. PMC: 85632. DOI: 10.1128/MCB.20.10.3396-3406.2000. View

Zhang Y, Turkson J, Smithgall T, Levitzki A, Kraker A, Krolewski J . Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem. 2000; 275(32):24935-44. DOI: 10.1074/jbc.M002383200. View

Metcalf D, Greenhalgh C, Viney E, Willson T, Starr R, Nicola N . Gigantism in mice lacking suppressor of cytokine signalling-2. Nature. 2000; 405(6790):1069-73. DOI: 10.1038/35016611. View

Shimoda K, Kato K, Aoki K, Matsuda T, Miyamoto A, Shibamori M . Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity. 2000; 13(4):561-71. DOI: 10.1016/s1074-7613(00)00055-8. View

Benistant C, Bourgaux J, Chapuis H, Mottet N, Roche S, Bali J . The COOH-terminal Src kinase Csk is a tumor antigen in human carcinoma. Cancer Res. 2001; 61(4):1415-20. View

Blume-Jensen P, Hunter T . Oncogenic kinase signalling. Nature. 2001; 411(6835):355-65. DOI: 10.1038/35077225. View

Sosinowski T, Killeen N, Weiss A . The Src-like adaptor protein downregulates the T cell receptor on CD4+CD8+ thymocytes and regulates positive selection. Immunity. 2001; 15(3):457-66. DOI: 10.1016/s1074-7613(01)00195-9. View

Savage D, Antman K . Imatinib mesylate--a new oral targeted therapy. N Engl J Med. 2002; 346(9):683-93. DOI: 10.1056/NEJMra013339. View

10.

Shimoda K, Tsutsui H, Aoki K, Kato K, Matsuda T, Numata A . Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood. 2002; 99(6):2094-9. DOI: 10.1182/blood.v99.6.2094. View

11.

Aligayer H, Boyd D, Heiss M, Abdalla E, Curley S, Gallick G . Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. 2002; 94(2):344-51. DOI: 10.1002/cncr.10221. View

12.

Shimoda K, Kamesaki K, Numata A, Aoki K, Matsuda T, Oritani K . Cutting edge: tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN-alpha-induced suppression of B lymphocyte formation. J Immunol. 2002; 169(9):4707-11. DOI: 10.4049/jimmunol.169.9.4707. View

13.

Cohen R . Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2003; 2(4):246-51. DOI: 10.3816/CCC.2003.n.006. View

14.

Bardelli A, Parsons D, Silliman N, Ptak J, Szabo S, Saha S . Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 2003; 300(5621):949. DOI: 10.1126/science.1082596. View

15.

Summy J, Gallick G . Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003; 22(4):337-58. DOI: 10.1023/a:1023772912750. View

16.

Lin S, Yeh K, Chen W, Chen H, Chen S, Chiou H . Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features. Oncol Rep. 2004; 11(2):341-8. View

17.

Saltz L, Meropol N, Loehrer Sr P, Needle M, Kopit J, Mayer R . Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22(7):1201-8. DOI: 10.1200/JCO.2004.10.182. View

18.

Frame M . Newest findings on the oldest oncogene; how activated src does it. J Cell Sci. 2004; 117(Pt 7):989-98. DOI: 10.1242/jcs.01111. View

19.

Fujitake S, Hibi K, Okochi O, Kodera Y, Ito K, Akiyama S . Aberrant methylation of SOCS-1 was observed in younger colorectal cancer patients. J Gastroenterol. 2004; 39(2):120-4. DOI: 10.1007/s00535-003-1262-0. View

20.

Boggon T, Eck M . Structure and regulation of Src family kinases. Oncogene. 2004; 23(48):7918-27. DOI: 10.1038/sj.onc.1208081. View